Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Myasthenia Gravis
Pharma
Argenx CEO confident company can achieve 'standalone' success
Armed with “pipeline in a product” efgartigimod, approved in generalized myasthenia gravis as Vyvgart, Argenx is confident it can triumph on its own.
Fraiser Kansteiner
Sep 14, 2022 9:30am
Argenx's Vyvgart launch faces 'fierce' Ultomiris battle: analyst
Jul 27, 2022 8:40am
Argenx's subcutaneous efgartigimod matches IV sibling in phase 3
Mar 22, 2022 7:55am
Argenx straddles the line between drug promotion and awareness
Mar 3, 2022 10:10am
J&J goes early on myasthenia gravis awareness push
Mar 1, 2022 9:25am
Argenx's Vyvgart is already winning neurologist support
Feb 17, 2022 11:10am
